logo
Scientists seek to save Florida's dying reefs with hardy nursery-grown coral

Scientists seek to save Florida's dying reefs with hardy nursery-grown coral

Yahoo24-05-2025

A taskforce of experts looking into the mass bleaching and decline of Florida's delicate coral reefs is planting more than 1,000 nursery-grown juveniles from the reef-building elkhorn species in a new effort to reverse the tide of destruction.
Record ocean heat in 2023 hastened the death spiral for reefs in the Florida Keys, which have lost 90% of their healthy coral cover over the last 40 years, largely because of the climate emergency, according to the National Oceanic and Atmospheric Administration (Noaa).
Marine biologists from the Keys Marine Laboratory of the University of South Florida (USF) partnered with scientists from Tampa's Florida Aquarium to develop a large-scale restoration project involving elkhorn coral, which is critically endangered but also one of the fastest-growing and most resilient species.
Earlier this month, the USF facility in Long Key, halfway along the ecologically fragile Florida Keys island chain, took delivery of 1,050 young elkhorn corals spawned between 2022 and 2023 at the aquarium's conservation and research center in Apollo Beach.
The corals are acclimatizing in temperature-regulated seawater beds in Long Key. They will be distributed to research partners including the Coral Restoration Foundation, the Mote Marine Laboratory, Reef Renewal USA, and Sustainable Oceans and Reefs for planting at seven designated offshore sites around the Keys during the next two months.
Teams will monitor their progress over the following months and years. While project managers say not all will survive, they hope some of the juveniles will thrive and grow, and the knowledge gleaned will help better inform future recovery efforts.
'Maybe there will only be 100 out there a year from now, but even if it's only one out of a hundred that survives that's particularly tough, we can propagate that one,' said Cindy Lewis, director of the Keys Marine Laboratory.
'We hope there will be some resistant babies in that batch. What I do know is that if we do nothing, we'll have done nothing, and nothing will happen.'
Noaa says elkhorn branches can grow up to almost 4in (10cm) a year, and the species is particularly resilient to high wave action. They grow on larger, foundation coral species such as boulder star coral and brain coral to provide what Lewis calls a 'jungle gym' for fish and other marine life.
Their planting along the Keys will also represent the closing of a circle, because the parent corals from which they were spawned were 'rescued' from the ocean ahead of the 2023 mass bleaching event.
Biologists at the Florida Aquarium served as de facto matchmakers for the elkhorn corals, which were spawned to be as genetically diverse as possible.
'The coral juveniles we just transferred are made up of many new mother and father combinations that we hope will be more resilient to future stressors,' Keri O'Neil, director of the aquarium's coral conservation program, said.
'Without human intervention, these parent corals would not be able to breed due to the extent of the loss. They're a sign that, even during a crisis, we can make a difference. By working together we're protecting a reef that's essential to our environment, our economy and the thousands of species that call it home.'
Lewis said the elkhorn project was a small component of a vast wider effort by numerous universities, environmental groups, and state and federal partners to try to restore as much lost coral as possible.
'Elkhorn is just one species of coral. Our partners are doing this for staghorn coral and others – the brain corals, star corals and boulder corals, the massive corals that build the mountains of reefs that these elkhorn and staghorn live on,' she said.
'All these different organizations produced over 25,000 pieces of coral this winter to put out on the reef that are going to make a difference, along with our elkhorn.
'Even though it seems dismal and depressing, the ray of hope is that we can produce these corals, we can get these corals out there, and that everybody has banded together to work together. No one organization is going to do it all. We need everybody, and we need everybody's ideas.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Frank Graham Jr., Nature Writer Who Updated ‘Silent Spring,' Dies at 100
Frank Graham Jr., Nature Writer Who Updated ‘Silent Spring,' Dies at 100

New York Times

time28 minutes ago

  • New York Times

Frank Graham Jr., Nature Writer Who Updated ‘Silent Spring,' Dies at 100

Frank Graham Jr., who wrote eloquently about the natural world and conservation for Audubon Magazine for nearly 50 years and published a book that updated Rachel Carson's groundbreaking 1962 exposé, 'Silent Spring,' which had warned about the dangers of pesticides, died on May 25 at his home in Milbridge, Maine. He was 100. David Seideman, a former editor in chief of Audubon, the magazine published by the National Audubon Society, confirmed the death. The subjects of Mr. Graham's writing 'ran the gamut,' Mr. Seideman said in an interview, 'from the tiniest creatures, like spiders — about which he was a self-taught expert — to giant sandhill cranes on Nebraska's Platte River. There wasn't a creature that didn't interest him.' He added, 'I'd visit him in Maine, where he had a little island, and we'd be eating plants, and he'd also be picking spiders out of his kayak and identifying them.' In addition to birds and insects, Mr. Graham wrote about threats to the environment. Ed Neal, the outdoors columnist for The San Francisco Examiner, described Mr. Graham's 1996 book, 'Disaster by Default: Politics and Water Pollution,' as 'a damning indictment of what industry and indifferent government have done to the nation's waterways.' Want all of The Times? Subscribe.

Ozempic Without Muscle Loss? New Drug Combo Trial Finds It's Possible
Ozempic Without Muscle Loss? New Drug Combo Trial Finds It's Possible

Gizmodo

time39 minutes ago

  • Gizmodo

Ozempic Without Muscle Loss? New Drug Combo Trial Finds It's Possible

Thinking about taking Ozempic but worried about losing too much muscle? New clinical trial data might point to a future where that's no longer a concern. Regeneron Pharmaceuticals announced the interim results of its Phase 2 COURAGE trial Monday, which tested a combination of semaglutide (the active ingredient in popular drugs Ozempic and Wegovy) and up to two antibodies designed to preserve muscle. Compared to people who only took semaglutide, those on the combination lost less lean mass and even appeared to shed a bit more weight. The findings will pave the way for larger trials of these drugs. Semaglutide and similar GLP-1 drugs have proven to be highly effective obesity and type 2 diabetes treatments. But like every drug, they have their possible trade-offs, including muscle loss. Experts have correctly argued that this side effect isn't truly unique to GLP-1s. Anytime we lose a significant amount of weight, we're likely to lose both fat and fat-free mass, also known as lean body mass. And research to date hasn't shown whether the lean body mass lost while taking GLP-1s can be linked to any actual health issues. That said, some clinical trial data has suggested that people taking semaglutide in particular can lose a bit more muscle than they might losing weight through other means (the proportion of lean body mass lost while losing weight has reached up to 40%). And there are certain populations more vulnerable to complications from losing too much muscle, such as older adults. So while the health risks of this effect aren't clear, doctors and drug companies have started to look for ways to mitigate it. Regeneron's strategy relies on two experimental lab-made antibodies, trevogrumab and garetosmab. Both antibodies are linked to separate proteins that play key roles in limiting skeletal muscle growth. Trevogrumab blocks myostatin, also known as GDF8, and garetosmab blocks activin A. The drugs are already being investigated as treatments for certain muscle- or bone-related conditions, but Regeneron reasoned that they could also be used to proactively prevent muscle loss while taking a GLP-1. The company's Phase 2 trial involved around 600 people with obesity. For the first half of the trial (26 weeks), the volunteers were divided into four groups: one group only given semaglutide, two groups given semaglutide and a lower or higher dose of trevogrumab, and a fourth given all three drugs at once. According to the company, people taking only semaglutide lost about 35% of their lean body mass by week 26. Those who took semaglutide with trevogrumab lost around 17%, while people on the full combination saw just a 7% loss. People taking all three drugs also lost the most weight (13% from their baseline compared to roughly 10% for the other groups). 'These early insights from the COURAGE trial…clearly establish the principle that blocking GDF8 with or without activin A can preserve muscle and further increase fat loss in patients being treated with GLP-1 therapy, thereby improving the quality of weight loss,' said George Yancopoulos, president and chief scientific officer at Regeneron, in a statement from the company. These results have yet to be vetted by outside scientists, and the data from the second half of the trial hasn't been fully analyzed (testing if trevogrumab alone can improve weight maintenance). People taking a higher dose of trevogrumab or the full three-drug combination also reported more adverse effects and dropped out of the study at a higher rate, suggesting that this combination strategy isn't without its own disadvantages. In the end, these are still early days for the company's novel approach to weight loss. Plenty of people are worried about the potential loss of muscle while taking GLP-1s, so there seems to be a willing audience for medications that can reduce this risk. And Regeneron isn't the only company or research team trying to find a workaround for it. So as impressive as Ozempic and its ilk have been, they can still be further improved.

Uncovering Unhealthy Drinking in ‘Normal' Patients
Uncovering Unhealthy Drinking in ‘Normal' Patients

Medscape

time43 minutes ago

  • Medscape

Uncovering Unhealthy Drinking in ‘Normal' Patients

Nathaniel Chin, MD Associate Professor, Department of Medicine, Division of Geriatrics and Gerontology; Associate Program Director, UW Health Memory Clinic; Medical Director, Wisconsin Alzheimer's Disease Research Study; Medical Director, Wisconsin Registry for Alzheimer's Prevention Study; Medical Director, ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI), University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin Disclosure: Nathaniel Chin, MD, has disclosed the following relevant financial relationships:Serve(d) as a consultant or advisor for: New Amsterdam Pharma Inc (1-day advisory panel, July 2023); Eli Lilly Inc (2-day advisory panel, January 2025) Serve(d) as a volunteer board member for: Medical and Scientific Board, Wisconsin Alzheimer's Association; Alzheimer's Foundation of America

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store